Leukemia, Myeloid: all 2,432 studies
Page 23 of 25. Open to participants first (205), then studies with results posted, then the rest; newest registration first within each.
- Stem Cell Transplantation for Patients With Hematologic MalignanciesCompletedNCT00152139Phase 3
- All-Trans Retinoic Acid in Combination With Standard Induction and Consolidation Therapy in Older Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT00151255Phase 3
- Study on All-Trans Retinoic Acid, Induction and Consolidation Therapy, and Pegfilgrastim After Consolidation Therapy in Younger Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT00151242Phase 2/3
- Standard vs. Reduced-Intensity Conditioning in Patients With Acute Myeloid Leukemia in First RemissionTerminatedNCT00150878Phase 3
- AFR10 - Combination Therapy of Imatinib Mesylate (IM) + Alpha-2A Interferon for Chronic Phase CML Patients Resistant or Refractory to IM Used as Single Therapy for at Least One YearStatus unknownNCT00146913Phase 2
- Risk-Adapted Therapy of Acute Myeloid Leukemia of Adults (18-60 Years) According to the Cytogenetic ResultCompletedNCT00146120Phase 3
- Haploidentical Stem Cell Transplant for Treatment Refractory Hematological MalignanciesCompletedNCT00145613Phase 2
- Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Related Stem Cell TransplantationCompletedNCT00144703Phase 2
- Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Un-Related Stem Cell TransplantationCompletedNCT00144677Phase 2
- Gemtuzumab Ozogamicin in Combination With A-HAM in Refractory AML (GO-A-HAM)CompletedNCT00143975Phase 2
- Stem Cell Transplantation as Immunotherapy for Hematologic MalignanciesCompletedNCT00143559Phase 2
- A Study of All-Trans Retinoic Acid (ATRA) and Bryostatin in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)CompletedNCT00136461Phase 2
- High Dose Ara-C (HDAC) and Interleukin-2 (IL-2) for Patients With Acute Myelogenous Leukemia (AML)CompletedNCT00136448Phase 2
- Study of Vaccination With Autologous Acute Myeloblastic Leukemia Cells in Patients With Advanced Myelodysplasia or Acute Myelogenous LeukemiaCompletedNCT00136422Phase 1
- Study of Unrelated Cord Blood Transplantation Using Tacrolimus and SirolimusCompletedNCT00133367Phase 2
- Sorafenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous LeukemiaCompletedNCT00131989Phase 1
- Study of Iressa in Patients With Relapsed or Refractory Acute Myelogenous LeukemiaCompletedNCT00130702Phase 2
- Study for Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)TerminatedNCT00129948Phase 2
- Zosuquidar in Combination With Daunorubicin and Cytarabine in Patients Ages 55-75 With Newly Diagnosed Acute Myeloid Leukemia (AML)CompletedNCT00129168Phase 1/2
- Study to Determine the Optimal Biologic Dose of CC-401 in Subjects With High-Risk Myeloid LeukemiaTerminatedNCT00126893Phase 1
- Cladribine, Cytarabine and Idarubicin in Patients With Relapsed Acute Myelocytic Leukemia (AML)Status unknownNCT00126321Phase 2
- Clofarabine in Adult Patients With Advanced Solid TumorsCompletedNCT00125840Phase 1
- Combination Chemotherapy and Tipifarnib in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaTerminatedNCT00124644Phase 1
- Cytarabine and Daunorubicin With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic SyndromesCompletedNCT00121303Phase 3
- Fludarabine, Total-Body Irradiation, and Donor Stem Cell Transplant Followed By Cyclosporine and Mycophenolate Mofetil in Treating Patients With Chronic Myelogenous LeukemiaCompletedNCT00119340Phase 1/2
- Vaccination in the Peripheral Stem Cell Transplant Setting for Acute Myelogenous LeukemiaCompletedNCT00116467Phase 2
- Trial Comparing Pegfilgrastim With Filgrastim as an Adjunct to Chemotherapy for Acute Myeloid Leukaemia (AML)CompletedNCT00114764Phase 2
- Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT00112853Phase 1
- BMS-354825 or Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Previous Imatinib MesylateStatus unknownNCT00112775Phase 2
- Cytarabine With or Without VNP40101M in Treating Patients With Relapsed Acute Myeloid LeukemiaCompletedNCT00112554Phase 3
- Therapy-Optimization Trial for the Treatment of Acute Myeloid Leukemias (AML) in Children and AdolescentsStatus unknownNCT00111345Phase 2/3
- Fludarabine and Radiation Therapy in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Phase or Accelerated Phase Chronic Myelogenous LeukemiaCompletedNCT00110058Phase 2
- Pixantrone (BBR 2778) in Patients With Refractory Acute Myelogenous Leukemia (AML)CompletedNCT00106600Phase 1/2
- Study of Troxatyl™ Administered by Continuous Infusion to Subjects With Refractory Acute Myelogenous Leukemia (AML)TerminatedNCT00104468Phase 1/2
- BMS-354825 in Patients With Chronic Accelerated, or Blast Phase Chronic Myelogenous Leukemia or Philadelphia Positive Acute Lymphoblastic LeukemiaCompletedNCT00103701Phase 1
- 17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic CancerTerminatedNCT00103272Phase 1
- Dasatinib (BMS-354825) in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic LeukemiaCompletedNCT00101595Phase 2
- Tipifarnib in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT00101296Phase 1
- Flavopiridol in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous LeukemiaTerminatedNCT00101231Phase 1
- MS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid LeukemiaCompletedNCT00101179Phase 1
- Tipifarnib, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid LeukemiaCompletedNCT00101153Phase 1
- Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia in RemissionWithdrawnNCT00101140Phase 2
- Temsirolimus and Imatinib Mesylate in Treating Patients With Chronic Myelogenous LeukemiaTerminatedNCT00101088Phase 1
- A Notch Signalling Pathway Inhibitor for Patients With T-cell Acute Lymphoblastic Leukemia/Lymphoma (ALL)(0752-013)TerminatedNCT00100152Phase 1
- SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic SyndromesCompletedNCT00098826Phase 1
- Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic SyndromesCompletedNCT00098423Phase 1
- Investigation of Clofarabine in Acute LeukemiasCompletedNCT00098033Phase 2
- Idarubicin and Cytarabine With or Without Bevacizumab in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaTerminatedNCT00096148Phase 2
- XK469R in Treating Patients With Refractory Hematologic CancerCompletedNCT00095797Phase 1
- Tipifarnib Versus Best Supportive Care in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)CompletedNCT00093990Phase 3
- Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid TumorsCompletedNCT00093821Phase 1
- Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed by Unrelated Donor Stem Cell Transplant in Treating Patients With Fanconi AnemiaCompletedNCT00093743Phase 1
- Everolimus and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Are Not in Complete Cytogenetic Remission After Previous Imatinib MesylateCompletedNCT00093639Phase 1/2
- PKC412, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT00093600Phase 1
- Arsenic Trioxide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid LeukemiaCompletedNCT00093483Phase 1
- S0432 Tipifarnib in Treating Older Patients With Acute Myeloid LeukemiaCompletedNCT00093418Phase 2
- Infusion of Specially Treated Umbilical Cord Stem Cells After Chemoradiation Treatment for Blood CancersCompletedNCT00089596Phase 1/2
- Cilengitide in Treating Patients With Acute Myeloid LeukemiaTerminatedNCT00089388Phase 2
- Gemtuzumab Ozogamicin and Cyclosporine in Treating Older Patients With Relapsed Acute Myeloid LeukemiaCompletedNCT00089050Phase 2
- Thymoglobulin to Prevent Acute Graft vs. Host Disease (GvHD) in Patients With Acute Lymphocytic Leukemia (ALL) or Acute Myelogenous Leukemia (AML) Receiving a Stem Cell TransplantCompletedNCT00088543Not applicable
- PTK 787 and Gleevec in Patients With AML, AMM, and CML-BPCompletedNCT00088231Phase 1/2
- Rebeccamycin Analog in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, or Chronic Myelogenous LeukemiaCompletedNCT00087204Phase 1
- Study Evaluating the Addition of Amifostine (Ethyol®) to Idarubicin and Cytosine Arabinoside in Older Patients With Acute Myeloid LeukemiaCompletedNCT00086099Phase 1/2
- CCI-779 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Chronic Myelogenous Leukemia in Blastic PhaseCompletedNCT00084916Phase 2
- VNP40101M in Treating Patients With Acute Myelogenous Leukemia or High-Risk MyelodysplasiaCompletedNCT00083187Phase 2
- Gleevec Trial in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous LeukemiaCompletedNCT00081926Phase 4
- Study of Clofarabine & Cytosine Arabinoside Therapy for Older Adults With Acute Myeloid LeukemiaCompletedNCT00081822Phase 1
- Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)CompletedNCT00079482Phase 2
- 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Young Patients With Relapsed or Refractory Solid Tumors or LeukemiaCompletedNCT00079404Phase 1
- Decitabine and Valproic Acid in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT00079378Phase 1
- Imatinib (Gleevec(Registered Trademark)) to Treat Chronic Myelomonocytic Leukemia and Atypical Chronic Myelogenous LeukemiaCompletedNCT00079313Phase 2
- Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell TransplantCompletedNCT00078858Phase 1/2
- Bortezomib in Treating Young Patients With Refractory or Recurrent LeukemiaCompletedNCT00077467Phase 1
- 3-AP and High-Dose Cytarabine in Treating Patients With Advanced Hematologic MalignanciesCompletedNCT00077181Phase 1
- Study of DT388GMCSF Fusion Protein in Acute Myelogenous Leukemia (AML) and Chronic Myelomonocytic Leukemia (CMML)TerminatedNCT00074750Phase 1
- Dosing Study of Ara-C/EL625/Idarubicin in Refractory and Relapsed AMLCompletedNCT00074737Phase 2
- Sargramostim in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Are Not in Complete Cytogenetic Remission Following Initial TreatmentCompletedNCT00072579Phase 2
- GTI-2040 and High-Dose Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid LeukemiaCompletedNCT00070551Phase 1
- Gemtuzumab Ozogamicin in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia Undergoing Remission Induction and Intensification TherapyCompletedNCT00070174Phase 2
- S0301 Cyclosporine, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid LeukemiaCompletedNCT00066794Phase 2
- Imatinib Mesylate and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Myelogenous LeukemiaCompletedNCT00066326Phase 1
- Clofarabine Plus Cytarabine in Patients With Previously Untreated Acute Myeloid Leukemia and High-risk Myelodysplastic SyndromeCompletedNCT00065143Phase 2
- Safety and Tolerance Study of Oral Doses of CT53518 to Treat Patients With Acute Myelogenous Leukemia (AML)CompletedNCT00064584Phase 1
- BMS-354825 in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Is Resistant to Imatinib MesylateCompletedNCT00064233Phase 1
- Romidepsin in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT00062075Phase 2
- Experimental Bone Marrow Transplant ProtocolCompletedNCT00061581Phase 2
- Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive CancerCompletedNCT00060372Phase 1
- AG-858 in Patients Who Are Cytogenetically Positive After Treatment With Gleevec™TerminatedNCT00058747Phase 2
- Imatinib Mesylate With or Without Interferon Alfa or Cytarabine Compared With Interferon Alfa Followed by Donor Stem Cell Transplant in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous LeukemiaCompletedNCT00055874Phase 3
- Imatinib Mesylate and Decitabine in Treating Patients With Chronic Myelogenous LeukemiaCompletedNCT00054431Phase 2
- FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or LeukemiaCompletedNCT00053963Phase 1
- Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Chronic Myelogenous LeukemiaCompletedNCT00053248Phase 1/2
- Irinotecan and Cytarabine in Treating Patients With Refractory or Recurrent Acute Myeloid Leukemia or Chronic Myelogenous LeukemiaCompletedNCT00053144Phase 1
- Therapeutic Allogeneic Lymphocytes and Aldesleukin in Treating Patients With High-Risk or Recurrent Myeloid Leukemia After Undergoing Donor Stem Cell TransplantTerminatedNCT00052598Phase 1/2
- Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell TransplantationCompletedNCT00052520Phase 1/2
- High-Dose Gleevec Alone or in Combination With Peg-Intron and GM-CSF in Early Phase Chronic Myelogenous Leukemia (CML)CompletedNCT00050531Phase 3
- Decitabine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid LeukemiaTerminatedNCT00049582Phase 1
- Oblimersen and Imatinib Mesylate in Treating Patients With Chronic Myelogenous LeukemiaCompletedNCT00049192Phase 2
- S0117 Gemtuzumab Ozogamicin Plus Cytarabine in Treating Patients With Relapsed Acute Myeloid LeukemiaCompletedNCT00049179Phase 2
- Therapy of Early Chronic Phase CML With GleevecCompletedNCT00048672Phase 2